



**NEW YORK STATE MEDICAID
PREFERRED DRUG PROGRAM
2015 THERAPEUTIC CLASS REVIEW**

The New York Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2015 as they pertain to the Preferred Drug Program (PDP). For the therapeutic classes (identified below) new relevant clinical and/or financial information, since the previous review of the class, is known to exist. DUR Board meeting agendas for 2015 are under development and will be posted on the Department of Health (DoH) web-site thirty (30) days prior to the meeting date.

Therapeutic Category	Therapeutic Class	Previous Review Date
Analgesics	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	April 24, 2014
	Opioid Dependence Agents	September 18, 2014
	Opioids – Long Acting	April 24, 2014
Cardiovascular	Angiotensin Converting Enzyme Inhibitors	March 11, 2010
	Niacin Derivatives	June 12, 2008
	Triglyceride Lowering Agents	June 27, 2013
Central Nervous System	Anticonvulsants – Second Generation	April 24, 2014
	Antipsychotics – Second Generation	April 24, 2014
	Central Nervous System Stimulants	April 24, 2014
	Multiple Sclerosis Agents	April 24, 2014
	Sedative Hypnotics/Sleep Agents	June 27, 2013
Dermatologic Agents	Actinic Keratosis	Initial Review
	Anti-Virals – Topical	February 26, 2009
	Psoriasis Agents – Topical	April 15, 2011
	Steroids, Topical – High Potency	June 16, 2011
Endocrine/Metabolic	Anabolic Steroids – Topical	June 27, 2013
	Glucagon-like Peptide-1 Agonists	June 15, 2012

Therapeutic Category	Therapeutic Class	Previous Review Date
	Insulin – Rapid-Acting	November 4, 2010
Hematologicals	Anticoagulants - Oral	September 18, 2014
	Erythropoiesis Stimulating Agents	April 29, 2010
	Platelet Inhibitors	April 24, 2014
Immunologics	Immunomodulators - Systemic	April 24, 2014
Ophthalmics	Antibiotics/Steroids – Ophthalmic	June 15, 2012
	Antihistamines – Ophthalmic	June 15, 2012
Renal/Genitourinary	Phosphate Binders/Regulators	April 24, 2014
	Urinary Tract Antispasmodics	June 27, 2013
Respiratory	Anticholinergics – COPD Agents	April 24, 2014
	Long Acting Beta-2 Adrenergic Agent - Inhaled	April 19, 2012
	Corticosteroids - Inhaled	April 24, 2014

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DoH proposes no changes to the established Commissioner’s final determinations. If interested parties have new relevant clinical information, please submit to the Medicaid Pharmacy Department (dur@health.ny.gov) in a timely manner. The DoH will consider any new relevant clinical information provided when developing future DUR Board meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on previous meeting agendas which may be viewed at http://www.health.ny.gov/health_care/medicaid/program

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence **is preferred, or placebo controlled when no head-to-head trials are available**).

Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

- Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to dur@health.ny.gov (please reference DUR Board re-review).
- Clinical information submitted in reference to a DUR Board meeting agenda must be received by the DoH no later than two (2) weeks prior to the meeting date or the DUR Board may not have ample time to review the information.

Please continue to monitor the DoH web-site for DUR Board meeting schedules and agendas. (http://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm)